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Uromodulin-
associated kidney 
diseases
Uromodulin (Tamm-Horsfall protein), 
a heavily glycosylated and GPI anchor-
linked protein, is the most abundant 
protein in normal human urine. It is 
expressed only in the kidney, specifi cally 
in the cells of the thick ascending limb 
of Henle’s loop, where it is sorted to 
the apical cell membrane. Its function 
remains to be clarifi ed, but knockout 
mouse models are predisposed to 
bladder infections, kidney stones, and 
nephrocalcinosis. Recently, mutations 
in the uromodulin gene were associated 
with familial juvenile hyperuricemic 
nephropathy and autosomal-dominant 
medullary cystic kidney disease type 
2. But these disorders are also linked 
to other loci. Vylet’al et al. studied 
19 aff ected families using linkage 
analysis. In this issue, they report that 
nine families showed linkage to the 
uromodulin locus. Subsequent analysis 
revealed missense mutations in six 
families. When expressed in vitro, all 
mutant proteins showed inability 
to appropriately reach the plasma 
membrane and retention of the protein 
in the endoplasmic reticulum. Of great 
interest is the authors’ novel fi nding 
that, of the aff ected families that had 
no linkage to the uromodulin locus (as 
well as the ones with linkage), all but 
one family had a markedly decreased 
urinary excretion of uromodulin as 
well as abnormal uromodulin staining 
in the kidney. Th ese results suggest 
that, regardless of their cause, defects in 
uromodulin biology could lead to 
a common renal disease phenotype. 
See page 1155.
Direct glucocorticoid 
effects in podocytes
Glucocorticoids, widely used to treat 
many forms of primary glomerular 
disease, oft en dramatically reduce 
proteinuria. Many glomerular diseases 
include evident immunological 
abnormalities; glucocorticoids have 
multiple actions on the immune 
response. Hence, the antiproteinuric 
action of glucocorticoids has been 
attributed to their eff ect on the immune 
system. However, glucocorticoids 
are extremely eff ective in reducing 
proteinuria in minimal-change 
nephrotic syndrome, a disease where 
the evidence for an infl ammatory 
response is scant. In an exciting 
manuscript, Xing and co-workers 
report that glucocorticoids have direct 
eff ects on podocytes, a critical type 
of cell in the regulation of glomerular 
capillary barrier. In studies carried out 
with a cell line of human podocytes, 
they found that dexamethasone 
upregulated the expression of nephrin 
and downregulated that of vascular 
endothelial growth factor, two critical 
proteins in the control of podocyte 
function. In addition, dexamethasone 
enhanced podocyte diff erentiation 
and survival. Although much remains 
to be explored, this work opens a new 
avenue of research on the eff ects of 
glucocorticoids on glomerular function. 
See page 1038.
Prostaglandin E2 
receptor agonists for 
treatment of kidney 
diseases
Th e kidney synthesizes several 
prostaglandins, prostaglandin E2 (PGE2) 
being one of the most prominent. 
Th is prostaglandin has been shown 
to be involved in the control of renal 
blood fl ow, glomerular fi ltration, renin 
secretion, and tubular salt and water 
transport, as well as having proliferation-
modulating eff ects. PGE2 exerts its 
eff ects via four diff erent receptors, EP1, 
EP2, EP3, and EP4. EP1 modulates 
intracellular calcium, and the other 
receptors regulate intracellular cyclic 
adenosine 5′- monophosphate (cAMP) 
levels; EP2 and EP4 increase cAMP and 
EP3 decreases it. Th e pharmaceutical 
industry has designed several PGE2 
receptor agonists. Vukicevic et al. fi nd 
that a highly selective agonist of EP4 
signifi cantly improved the survival of 
rats with mercury chloride acute renal 
failure, lowered their serum creatinine, 
and reduced necrosis and apoptosis of 
tubular cells. Similarly, the compound 
was also eff ective in preserving 
kidney function and morphology in 
a fi ve-sixths nephrectomy model of 
chronic renal failure. Other receptor 
agonists showed a variable degree of 
effi  cacy. Th ese unexpected and as-yet 
unexplained results raise the possibility 
that manipulation of the prostaglandin 
system may off er a novel avenue for 
renal-protection therapy. See page 1099.
